What is ENZO BIOCHEM INC's earnings per share (EPS)?

ENZO BIOCHEM INC (ENZB) reported diluted earnings per share of -$0.51 for fiscal year 2024. This represents a -224.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ENZO BIOCHEM INC (ENZB) Financials

ENZB

Trailing 12 months to April 30, 2025

Revenue $27.5M -17.6% YoY

Net Income -$21.1M -147.1% YoY

EPS (Diluted) -$0.41 -144.6% YoY

Free Cash Flow -$16.3M +62.2% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2025, ended Apr 30, 2025 Reported Jun 16, 2025 Currency USD FYE July

Newest figures come from the 10-Q for Q3 FY2025, filed Jun 16, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ENZB SEC filings page.

ENZO BIOCHEM INC (ENZB) reported $27.5M in revenue over the twelve months to Apr 30, 2025, down 17.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ENZB FY2024 2026-09-05

Operating losses remain the central mechanic: improved gross margins and lower overhead have not yet translated into positive cash generation.

FY2023 paired $20.3M of net income with -$37.0M of operating cash flow, while FY2024's -$26.1M loss closely matched -$26.3M of operating cash flow. The contrast suggests FY2023 earnings were shaped by non-operating or non-cash items, whereas FY2024 more directly reflected the business's cash-consuming operations.

Gross margin expanded from 42.5% in FY2023 to 45.9% in FY2024, while the operating loss margin improved from -79.6% to -38.8%. This combination points to lower overhead burden and better gross economics, but the remaining operating deficit shows the cost base still exceeds what gross profit supports.

The balance sheet is lightly debt-funded: debt-to-equity remained at 0.3% while the current ratio was 2.8x in FY2024. Reported cash, equivalents, and investments equaled 23.9 months of the latest annual operating outflow at year-end, so liquidity was supported more by accumulated liquid resources than borrowing.

Financial Health Signals

Financial health score not available

ENZO BIOCHEM INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-3.54

ENZO BIOCHEM INC scores -3.54, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($36.6M) relative to total liabilities ($29.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

ENZO BIOCHEM INC passes 4 of 9 financial strength tests. No profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

ENZO BIOCHEM INC reported a net loss of $26.1M while operations used $26.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

ENZO BIOCHEM INC reported an operating loss of $12.4M against $197K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.4M

YoY-20.2%

QoQ-12.7%

ENZO BIOCHEM INC generated $6.4M in revenue in Q3 2025. This represents a decrease of 20.2% from the same quarter a year earlier. Against the prior quarter it is down 12.7%.

EBITDA

-$3.1M

YoY-80.0%

ENZO BIOCHEM INC's EBITDA was -$3.1M in Q3 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 80.0% from the same quarter a year earlier.

Net Income

-$2.8M

YoY+7.6%

QoQ-81.8%

ENZO BIOCHEM INC reported -$2.8M in net income in Q3 2025. This represents an increase of 7.6% from the same quarter a year earlier. Against the prior quarter it is down 81.8%.

EPS (Diluted)

-$0.05

YoY+16.7%

QoQ-66.7%

ENZO BIOCHEM INC earned -$0.05 per diluted share (EPS) in Q3 2025. This represents an increase of 16.7% from the same quarter a year earlier. Against the prior quarter it is down 66.7%.

Cash & Balance Sheet

Free Cash Flow

-$3.6M

YoY-20.0%

QoQ-72.0%

ENZO BIOCHEM INC recorded an outflow of $3.6M in free cash flow in Q3 2025, representing a cash shortfall after capex. This represents a decrease of 20.0% from the same quarter a year earlier. Against the prior quarter it is down 72.0%.

Cash & Debt

$36.7M

YoY-35.8%

QoQ-8.9%

5Y CAGR-7.6%

ENZO BIOCHEM INC held $36.7M in cash against $129K in long-term debt as of Q3 2025.

Shares Outstanding

52M

YoY+1.8%

QoQ0.0%

5Y CAGR+1.8%

10Y CAGR+1.3%

ENZO BIOCHEM INC had 52M shares outstanding in Q3 2025. This represents an increase of 1.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2025.

Margins & Returns

Gross Margin

41.3%

YoY-5.2pp

ENZO BIOCHEM INC's gross margin was 41.3% in Q3 2025, indicating the percentage of revenue retained after direct costs. This is down 5.2 percentage points from the same quarter a year earlier.

Operating Margin

-52.9%

YoY-27.5pp

QoQ-31.1pp

ENZO BIOCHEM INC's operating margin was -52.9% in Q3 2025, reflecting core business profitability. This is down 27.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 31.1 percentage points.

Net Margin

-43.6%

YoY-5.9pp

QoQ-22.7pp

ENZO BIOCHEM INC's net profit margin was -43.6% in Q3 2025, showing the share of revenue converted to profit. This is down 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 22.7 percentage points.

Return on Equity

-6.4%

YoY-2.1pp

QoQ-3.1pp

ENZO BIOCHEM INC's ROE was -6.4% in Q3 2025, measuring profit generated per dollar of shareholder equity. This is down 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.1 percentage points.

Capital Allocation

R&D Spending

$504K

YoY-16.7%

QoQ+5.2%

ENZO BIOCHEM INC invested $504K in research and development in Q3 2025. This represents a decrease of 16.7% from the same quarter a year earlier. Against the prior quarter it is up 5.2%.

Capital Expenditures

$386K

YoY+169.9%

QoQ+451.4%

5Y CAGR+6.3%

10Y CAGR-2.8%

ENZO BIOCHEM INC invested $386K in capex in Q3 2025, funding long-term assets and infrastructure. This represents an increase of 169.9% from the same quarter a year earlier. Against the prior quarter it is up 451.4%.

Share Buybacks

Not reported for Q3 2025.

ENZB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENZB quarterly income statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Revenue	$27.5M	$31.9M+2.7%	$31.1M-4.8%	$32.6M-72.3%	$117.7M+54.9%	$76.0M-6.3%	$81.2M-19.6%	$101.0M-3.9%	$105.1M+2.3%	$102.8M+5.3%	$97.6M+1.7%	$95.9M+2.4%	$93.7M-9.1%	$103.1M+1.0%	$102.0M+5.1%	$97.1M
Cost of Revenue	N/A	$17.3M-3.3%	$17.9M-7.0%	$19.2M-70.1%	$64.2M+22.8%	$52.3M-9.8%	$57.9M-4.1%	$60.4M+1.5%	$59.5M+315.0%	$14.3M-5.6%	$15.2M-0.9%	$15.3M-7.6%	$16.6M-15.7%	$19.7M-11.2%	$22.1M-1.8%	$22.5M
Gross Profit	N/A	$14.6M+10.9%	$13.2M-1.7%	$13.4M-74.9%	$53.6M+125.4%	$23.8M+2.2%	$23.2M-42.8%	$40.6M-10.9%	$45.6M-48.4%	$88.4M+7.3%	$82.4M+2.2%	$80.6M+4.5%	$77.1M-7.5%	$83.4M+4.4%	$79.9M+7.2%	$74.5M
R&D Expenses	$2.2M	$2.6M-32.3%	$3.9M+60.1%	$2.4M-25.0%	$3.3M-26.9%	$4.4M+40.1%	$3.2M-1.1%	$3.2M+9.6%	$2.9M-16.9%	$3.5M+5.2%	$3.4M+6.7%	$3.1M-19.2%	$3.9M-38.2%	$6.3M-19.4%	$7.8M-19.6%	$9.7M
SG&A Expenses	$19.5M	$21.7M-20.1%	$27.2M+17.8%	$23.1M-48.6%	$44.9M+4.5%	$43.0M-2.9%	$44.3M-0.4%	$44.5M+0.7%	$44.1M+0.9%	$43.7M+6.5%	$41.1M-1.8%	$41.8M-4.2%	$43.7M-8.9%	$47.9M+6.1%	$45.2M-6.6%	$48.4M
Operating Income	-$11.3M	-$12.4M+50.0%	-$24.7M-45.3%	-$17.0M-2560.5%	$692K+102.3%	-$30.4M-1852.3%	$1.7M+114.2%	-$12.2M-286.4%	-$3.1M-106.7%	$46.8M+3984.6%	-$1.2M+88.2%	-$10.2M+46.4%	-$19.0M+53.1%	-$40.5M-213.1%	-$12.9M+41.4%	-$22.1M
EBITDA	N/A	-$11.1M+49.7%	-$22.1M-52.5%	-$14.5M-578.2%	$3.0M+110.8%	-$28.1M-689.5%	$4.8M+152.8%	-$9.0M-2107.6%	$450K-99.1%	$50.7M+1862.4%	$2.6M+141.6%	-$6.2M+56.8%	-$14.4M+60.1%	-$36.0M-325.6%	-$8.5M+52.4%	-$17.8M
Interest Expense	N/A	$197K-82.4%	$1.1M+730.3%	-$178K-160.1%	$296K-43.5%	$524K-50.4%	$1.1M+23.8%	$853K	N/A	N/A	N/A	N/A	-$54K-357.1%	$21K+90.9%	$11K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.1M-1437.8%	$82K-92.4%	$1.1M+15442.9%	-$7K-109.7%	$72K+110.1%	-$712K+56.9%	-$1.7M-1305.8%	$137K+589.3%	-$28K
Net Income	-$21.1M	-$26.1M-228.5%	$20.3M+211.1%	-$18.3M-331.9%	$7.9M+127.6%	-$28.5M-1245.8%	$2.5M+124.1%	-$10.3M-312.2%	-$2.5M-105.5%	$45.3M+2081.9%	-$2.3M+77.1%	-$10.0M+45.3%	-$18.2M+53.6%	-$39.3M-203.0%	-$13.0M+41.7%	-$22.2M
EPS (Basic)	N/A	-$0.51-224.4%	$0.41+207.9%	-$0.38-337.5%	$0.16+126.7%	-$0.60-1300.0%	$0.05+122.7%	-$0.22-340.0%	-$0.05-105.1%	$0.98+2060.0%	-$0.05+78.3%	-$0.23	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.41	-$0.51-224.4%	$0.41+207.9%	-$0.38-337.5%	$0.16+126.7%	-$0.60-1300.0%	$0.05+122.7%	-$0.22-340.0%	-$0.05-105.2%	$0.97+2040.0%	-$0.05+78.3%	-$0.23	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	50,902+3.5%	49,160+1.2%	48,594+0.6%	48,325+1.3%	47,696-99.9%	47M+100973.0%	46,972-99.9%	46M-0.5%	47M+2.7%	45M+6.6%	43M+7.5%	40M+101985.2%	38,798+1.1%	38,357+0.9%	38,001

Metric	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K
Revenue	$6.4M-20.2%	$7.3M-14.3%	$6.2M-20.4%	$7.5M-16.0%	$8.0M+7.2%	$8.6M+13.8%	$7.8M+9.9%	$9.0M
Cost of Revenue	$3.8M-12.5%	N/A	$3.7M-15.4%	$4.3M+2.9%	$4.3M-4.2%	$4.3M-6.2%	$4.4M-5.2%	$4.2M
Gross Profit	$2.6M-29.1%	N/A	$2.5M-26.7%	$3.2M-32.6%	$3.7M+24.1%	$4.2M+45.8%	$3.5M+37.4%	$4.8M
R&D Expenses	$504K-16.7%	$479K-17.4%	$562K-33.8%	$608K-49.2%	$605K-31.6%	$580K-48.4%	$849K+21.5%	$1.2M
SG&A Expenses	$4.9M+9.5%	$4.6M-10.1%	$4.9M-30.3%	$5.2M-48.9%	$4.5M-27.9%	$5.1M-6.7%	$7.0M+28.9%	$10.1M
Operating Income	-$3.4M-65.9%	-$1.6M+26.7%	-$3.6M+33.9%	-$2.7M+63.1%	-$2.0M+75.5%	-$2.2M+51.9%	-$5.5M-18.3%	-$7.2M
EBITDA	-$3.1M-80.0%	N/A	-$3.3M+36.6%	N/A	-$1.7M+77.9%	N/A	-$5.2M-35.3%	-$6.6M
Interest Expense	N/A	N/A	N/A	$2.8M+128.7%	-$726K-2116.7%	-$893K-1317.5%	-$977K-1256.9%	$1.2M
Net Income	-$2.8M+7.6%	-$1.5M+49.9%	-$3.4M+49.0%	-$13.4M-123.3%	-$3.0M+80.1%	-$3.1M+73.0%	-$6.6M+37.8%	$57.4M
EPS (Basic)	-$0.05+16.7%	-$0.03+50.0%	-$0.07+46.2%	-$0.26-122.2%	-$0.06+80.6%	-$0.06+73.9%	-$0.13+40.9%	$1.17+750.0%
EPS (Diluted)	-$0.05+16.7%	-$0.03+50.0%	-$0.07+46.2%	-$0.26-122.2%	-$0.06+80.6%	-$0.06+73.9%	-$0.13+40.9%	$1.17+750.0%
Diluted Shares (Avg)	52,403+2.3%	52,297+3.6%	52,244+4.1%	N/A	51,214+3.7%	50,490+3.6%	50,184+3.0%	N/A

Not reported in any period shown, so not listed: Income Tax.

ENZB Balance Sheet

ENZB quarterly balance sheet

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Total Assets	$85.8M-29.6%	$121.9M+61.2%	$75.6M-33.5%	$113.7M+1.0%	$112.5M+5.5%	$106.6M+4.9%	$101.7M-5.6%	$107.7M-3.7%	$111.8M+63.5%	$68.4M+6.2%	$64.4M+9.2%	$59.0M-14.7%	$69.1M-36.9%	$109.5M	N/A
Current Assets	$70.0M-28.9%	$98.5M+129.9%	$42.8M-39.3%	$70.6M+2.6%	$68.8M-15.6%	$81.5M-2.1%	$83.2M-6.6%	$89.1M-2.5%	$91.4M+96.6%	$46.5M+14.1%	$40.7M+25.1%	$32.6M-19.4%	$40.4M-21.5%	$51.4M	N/A
Cash & Equivalents	$52.4M-36.4%	$82.4M+281.3%	$21.6M+59.7%	$13.5M-71.7%	$47.9M-20.4%	$60.1M+0.2%	$60.0M-6.4%	$64.2M-5.3%	$67.8M+274.3%	$18.1M+3.7%	$17.5M+93.8%	$9.0M-40.3%	$15.1M+6.5%	$14.2M+61.7%	$8.8M
Short-Term Investments	$0	$0	$0-100.0%	$30.0M	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$10.0M	$0
Inventory	$6.8M-13.9%	$7.9M-16.6%	$9.5M-24.8%	$12.7M+62.5%	$7.8M-0.7%	$7.8M+7.7%	$7.3M+3.3%	$7.0M+1.1%	$7.0M-5.7%	$7.4M-14.9%	$8.7M-1.3%	$8.8M+0.1%	$8.8M-5.0%	$9.3M	N/A
Accounts Receivable	$4.0M-17.1%	$4.8M+1.0%	$4.8M-53.3%	$10.2M+11.6%	$9.1M-14.9%	$10.7M-18.3%	$13.1M-13.4%	$15.2M+4.0%	$14.6M+20.5%	$12.1M-2.9%	$12.5M+1.5%	$12.3M-13.1%	$14.1M-7.3%	$15.2M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M-72.8%	$27.4M+9.7%	$24.9M
Total Liabilities	$29.7M-31.7%	$43.4M+105.3%	$21.1M-53.1%	$45.1M-16.7%	$54.2M+162.7%	$20.6M+0.4%	$20.5M+9.3%	$18.8M-15.6%	$22.3M-13.7%	$25.8M-6.1%	$27.5M+10.6%	$24.8M+24.0%	$20.0M-3.6%	$20.8M	N/A
Current Liabilities	$24.8M-38.0%	$40.0M+207.2%	$13.0M-50.1%	$26.1M-20.5%	$32.8M+104.9%	$16.0M-20.7%	$20.2M+13.3%	$17.8M-13.4%	$20.6M-14.1%	$24.0M-4.0%	$25.0M+4.7%	$23.9M+25.8%	$19.0M+6.9%	$17.7M	N/A
Non-Current Liabilities	$4.9M+41.7%	$3.4M-57.8%	$8.1M-57.3%	$19.0M-10.9%	$21.4M+364.0%	$4.6M+1204.0%	$353K-64.1%	$983K-42.1%	$1.7M-7.2%	$1.8M-26.7%	$2.5M+156.3%	$974K-8.6%	$1.1M-64.8%	$3.0M	N/A
Long-Term Debt	$189K-29.7%	$269K-93.4%	$4.1M-6.4%	$4.4M-2.9%	$4.5M+7.3%	$4.2M+208850.0%	$2K-90.9%	$22K-79.0%	$105K-71.1%	$363K-1.6%	$369K+37.2%	$269K	N/A	N/A	N/A
Total Equity	$56.1M-28.5%	$78.5M+44.1%	$54.5M-20.6%	$68.6M+17.5%	$58.4M-32.1%	$86.0M+6.0%	$81.1M-8.7%	$88.9M-0.8%	$89.6M+110.2%	$42.6M+15.3%	$37.0M+8.3%	$34.1M-30.5%	$49.1M-44.7%	$88.7M-8.6%	$97.0M
Retained Earnings	-$294.4M-9.7%	-$268.4M+7.0%	-$288.6M-6.8%	-$270.4M+2.8%	-$278.3M-11.4%	-$249.7M+1.0%	-$252.2M-4.3%	-$241.9M-1.0%	-$239.4M+15.9%	-$284.7M-0.8%	-$282.4M-3.7%	-$272.4M-7.2%	-$254.2M-18.3%	-$214.9M	N/A

Metric	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K
Total Assets	$63.5M-32.0%	$67.5M-31.9%	$75.3M-29.2%	$85.8M-29.6%	$93.5M+29.7%	$99.1M+29.6%	$106.3M+24.8%	$121.9M+61.2%
Current Assets	$48.3M-36.3%	$52.2M-35.5%	$59.7M-32.2%	$70.0M-28.9%	$75.7M+136.7%	$80.9M+122.4%	$88.0M+97.4%	$98.5M+129.9%
Cash & Equivalents	$36.7M-35.8%	$40.3M-33.1%	$47.7M-31.0%	$52.4M-36.4%	$57.2M+2071.6%	$60.2M+1091.9%	$69.2M+470.3%	$82.4M+281.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$5.7M-22.0%	$6.0M-23.2%	$6.4M-15.9%	$6.8M-13.9%	$7.3M-52.1%	$7.8M-50.4%	$7.6M-51.9%	$7.9M-16.6%
Accounts Receivable	$4.3M+9.5%	$4.2M-17.0%	$3.8M-8.1%	$4.0M-17.1%	$3.9M-59.2%	$5.1M-52.9%	$4.2M-63.7%	$4.8M+1.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$20.1M-17.7%	$20.9M-26.2%	$27.6M-13.7%	$29.7M-31.7%	$24.4M-54.0%	$28.3M-35.1%	$32.0M-20.3%	$43.4M+105.3%
Current Liabilities	$17.0M-21.5%	$17.2M-32.1%	$23.4M-18.9%	$24.8M-38.0%	$21.7M-48.6%	$25.3M-21.5%	$28.8M+18.9%	$40.0M+207.2%
Non-Current Liabilities	$3.1M+12.0%	$3.7M+23.2%	$4.2M+32.7%	$4.9M+41.7%	$2.8M-74.7%	$3.0M-73.6%	$3.2M-80.0%	$3.4M-57.8%
Long-Term Debt	$129K-28.3%	$146K-37.6%	$155K-29.2%	$189K-29.7%	$180K-27.1%	$234K-19.0%	$219K-94.5%	$269K-93.4%
Total Equity	$43.4M-37.1%	$46.6M-34.1%	$47.7M-35.8%	$56.1M-28.5%	$69.0M+264.7%	$70.8M+115.6%	$74.3M+65.1%	$78.5M+44.1%
Retained Earnings	-$302.1M-7.5%	-$299.3M-7.7%	-$297.8M-8.3%	-$294.4M-9.7%	-$281.0M+13.7%	-$278.0M+10.5%	-$275.0M+8.1%	-$268.4M+7.0%

Not reported in any period shown, so not listed: Goodwill.

ENZB Cash Flow Statement

ENZB quarterly cash flow statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Operating Cash Flow	-$15.3M	-$26.3M+29.0%	-$37.0M-122.9%	-$16.6M-4386.8%	$387K+102.3%	-$17.2M-457.4%	$4.8M+275.7%	-$2.7M-1234.1%	-$205K-100.4%	$53.1M+1535.8%	-$3.7M-118.0%	-$1.7M+83.1%	-$10.0M-67.7%	-$6.0M+28.3%	-$8.3M+38.2%	-$13.5M
Depreciation & Amortization	N/A	$1.3M-52.6%	$2.7M+4.5%	$2.6M+10.0%	$2.3M+3.4%	$2.3M-25.7%	$3.0M-3.0%	$3.1M-13.0%	$3.6M-6.3%	$3.8M+1.3%	$3.8M-4.6%	$4.0M-13.8%	$4.6M+2.9%	$4.5M+0.2%	$4.5M+4.7%	$4.3M
Stock-Based Compensation	N/A	$1.7M-25.2%	$2.3M+74.7%	$1.3M+43.1%	$907K-2.8%	$933K-0.6%	$939K+15.5%	$813K-2.2%	$831K+58.3%	$525K+22.4%	$429K-27.8%	$594K+9.0%	$545K-24.2%	$719K-31.5%	$1.0M-10.3%	$1.2M
Capital Expenditures	$1.0M	$545K-80.3%	$2.8M-20.5%	$3.5M-21.7%	$4.4M+104.4%	$2.2M-73.3%	$8.1M+330.4%	$1.9M+7.7%	$1.8M+14.6%	$1.5M-14.2%	$1.8M+112.8%	$838K-15.2%	$988K-27.6%	$1.4M+11.5%	$1.2M-62.4%	$3.3M
Free Cash Flow	-$16.3M	-$26.8M+32.5%	-$39.7M-98.1%	-$20.1M-395.5%	-$4.0M+79.1%	-$19.3M-482.8%	-$3.3M+28.2%	-$4.6M-136.1%	-$2.0M-103.8%	$51.6M+1041.0%	-$5.5M-116.3%	-$2.5M+77.0%	-$11.0M-50.0%	-$7.3M+23.2%	-$9.5M+42.9%	-$16.7M
Investing Cash Flow	$4.0M	-$545K-100.6%	$99.0M+292.4%	$25.2M+173.1%	-$34.5M-1489.7%	-$2.2M+73.3%	-$8.1M-318.0%	-$1.9M-11.1%	-$1.7M-15.7%	-$1.5M+13.7%	-$1.8M-110.3%	-$833K+14.2%	-$971K-113.0%	$7.5M-44.9%	$13.5M-11.7%	$15.3M
Financing Cash Flow	-$9.2M	-$4.2M-272.7%	-$1.1M-366.8%	-$241K+0.4%	-$242K-103.5%	$7.0M+67.0%	$4.2M+650.1%	$559K+133.5%	-$1.7M+13.6%	-$1.9M-131.0%	$6.2M-43.0%	$10.9M+126.7%	$4.8M+3226.6%	-$154K-126.5%	-$68K	N/A

Metric	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K
Operating Cash Flow	-$3.2M-12.5%	-$2.0M+77.3%	-$9.0M+32.8%	-$1.1M+93.6%	-$2.9M+43.4%	-$8.9M-44.2%	-$13.4M-53.8%	-$17.0M-87.8%
Depreciation & Amortization	$318K-5.6%	N/A	$319K+18.1%	N/A	$337K-48.0%	N/A	$270K-65.4%	$606K-7.6%
Stock-Based Compensation	$174K-15.9%	$181K-30.7%	$171K-84.1%	N/A	$207K-63.2%	$261K-49.3%	$1.1M+150.0%	N/A
Capital Expenditures	$386K+169.9%	$70K+180.0%	$448K+76.4%	$123K-78.5%	$143K-78.5%	$25K-97.1%	$254K-61.0%	$573K+55.3%
Free Cash Flow	-$3.6M-20.0%	-$2.1M+76.6%	-$9.4M+30.7%	-$1.2M+93.1%	-$3.0M+47.5%	-$9.0M-26.8%	-$13.6M-45.8%	-$17.6M-86.5%
Investing Cash Flow	-$386K-169.9%	-$70K-180.0%	$4.6M+1892.1%	-$123K-100.1%	-$143K+78.5%	-$25K+97.1%	-$254K+61.0%	$101.2M+27516.5%
Financing Cash Flow	-$42K+4.5%	-$5.3M-24100.0%	-$200K+61.4%	-$3.6M+14.9%	-$44K-101.3%	-$22K+64.5%	-$518K-445.3%	-$4.2M-4316.7%
Dividends Paid	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Share Buybacks.

ENZB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENZB quarterly financial ratios

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Gross Margin	45.9%+3.4pp	42.5%+1.3pp	41.1%-4.4pp	45.5%+14.2pp	31.3%+2.6pp	28.6%-11.6pp	40.2%-3.2pp	43.4%-42.7pp	86.1%+1.6pp	84.4%+0.4pp	84.0%+1.7pp	82.3%+1.4pp	80.9%+2.6pp	78.3%+1.5pp	76.8%
Operating Margin	-38.8%+40.9pp	-79.6%-27.5pp	-52.2%-52.8pp	0.6%+40.5pp	-40.0%-42.1pp	2.1%+14.2pp	-12.0%-9.0pp	-3.0%-48.6pp	45.6%+46.8pp	-1.2%+9.4pp	-10.6%+9.6pp	-20.3%+19.0pp	-39.3%-26.6pp	-12.7%+10.1pp	-22.7%
Net Margin	-81.7%-147.0pp	65.3%+121.3pp	-55.9%-62.6pp	6.7%+44.2pp	-37.5%-40.6pp	3.1%+13.3pp	-10.2%-7.8pp	-2.4%-46.4pp	44.1%+46.4pp	-2.3%+8.1pp	-10.4%+9.1pp	-19.5%+18.6pp	-38.1%-25.4pp	-12.7%+10.2pp	-22.9%
Return on Equity	-46.5%-72.3pp	25.9%+59.4pp	-33.5%-45.0pp	11.5%+60.3pp	-48.9%-51.7pp	2.9%+15.6pp	-12.7%-9.9pp	-2.8%-53.4pp	50.6%+55.9pp	-5.4%+21.6pp	-27.0%+26.4pp	-53.4%+26.5pp	-80.0%-65.4pp	-14.6%+8.3pp	-22.9%
Return on Assets	-30.4%-47.1pp	16.7%+40.8pp	-24.1%-31.1pp	6.9%+32.3pp	-25.3%-27.7pp	2.3%+12.5pp	-10.2%-7.8pp	-2.3%-42.8pp	40.5%+43.8pp	-3.3%+12.2pp	-15.5%+15.4pp	-30.9%+25.9pp	-56.8%-45.0pp	-11.8%	N/A
Current Ratio	2.82+0.4x	2.46-0.8x	3.29+0.6x	2.71+0.6x	2.10-3.0x	5.09+1.0x	4.12-0.9x	5.00+0.6x	4.44+2.5x	1.94+0.3x	1.63+0.3x	1.36-0.8x	2.13-0.8x	2.90	N/A
Debt-to-Equity	0.000.0x	0.00-0.1x	0.070.0x	0.060.0x	0.080.0x	0.050.0x	0.000.0x	0.000.0x	0.000.0x	0.010.0x	0.010.0x	0.01-0.4x	0.41+0.2x	0.23	N/A
Asset Turnover	0.37+0.1x	0.25-0.2x	0.43-0.6x	1.04+0.4x	0.68-0.1x	0.76-0.2x	0.990.0x	0.98+0.1x	0.92-0.5x	1.43-0.1x	1.49-0.1x	1.59+0.1x	1.49+0.6x	0.93	N/A
FCF Margin	-84.0%	-127.9%	-61.5%-58.0pp	-3.4%+22.0pp	-25.4%-21.4pp	-4.1%+0.5pp	-4.6%-2.7pp	-1.9%-52.1pp	50.2%+55.8pp	-5.6%-3.0pp	-2.6%+9.1pp	-11.7%-4.6pp	-7.1%+2.2pp	-9.4%+7.9pp	-17.2%

Metric	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K
Gross Margin	41.3%-5.2pp	N/A	40.8%-3.5pp	42.8%-10.5pp	46.5%+6.3pp	49.4%+10.8pp	44.3%+8.9pp	53.3%
Operating Margin	-52.9%-27.5pp	-21.8%+3.7pp	-58.3%+11.9pp	-35.4%+45.1pp	-25.5%	-25.6%+34.9pp	-70.2%-5.0pp	-80.5%
Net Margin	-43.6%-5.9pp	-20.9%+14.9pp	-54.3%+30.4pp	-177.8%	-37.6%	-35.8%	-84.8%	641.0%
Return on Equity	-6.4%-2.1pp	-3.3%+1.0pp	-7.1%+1.8pp	-23.8%-97.0pp	-4.4%+75.9pp	-4.3%+30.2pp	-8.9%+14.7pp	73.2%
Return on Assets	-4.4%-1.2pp	-2.3%+0.8pp	-4.5%+1.7pp	-15.6%-62.7pp	-3.2%+17.8pp	-3.1%+11.7pp	-6.2%+6.3pp	47.1%
Current Ratio	2.84-0.7x	3.04-0.2x	2.55-0.5x	2.82+0.4x	3.50+2.7x	3.20+2.1x	3.05+1.2x	2.46-0.8x
Debt-to-Equity	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00-0.1x	0.00-0.1x
Asset Turnover	0.100.0x	0.110.0x	0.080.0x	0.090.0x	0.090.0x	0.090.0x	0.070.0x	0.07
FCF Margin	-56.3%-18.9pp	-28.6%	-151.9%	-16.1%	-37.5%+39.0pp	-104.8%	-174.6%	-196.5%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.

Where ENZO BIOCHEM INC Ranks

Frequently Asked Questions

What is ENZO BIOCHEM INC's annual revenue?

ENZO BIOCHEM INC (ENZB) reported $31.9M in total revenue for fiscal year 2024. This represents a 2.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ENZO BIOCHEM INC's revenue growing?

ENZO BIOCHEM INC (ENZB) revenue grew by 2.7% year-over-year, from $31.1M to $31.9M in fiscal year 2024.

Is ENZO BIOCHEM INC profitable?

No, ENZO BIOCHEM INC (ENZB) reported a net income of -$26.1M in fiscal year 2024, with a net profit margin of -81.7%.

What is ENZO BIOCHEM INC's EBITDA?

ENZO BIOCHEM INC (ENZB) had EBITDA of -$11.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does ENZO BIOCHEM INC have?

As of fiscal year 2024, ENZO BIOCHEM INC (ENZB) had $52.4M in cash and equivalents against $189K in long-term debt.

What is ENZO BIOCHEM INC's gross margin?

ENZO BIOCHEM INC (ENZB) had a gross margin of 45.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is ENZO BIOCHEM INC's operating margin?

ENZO BIOCHEM INC (ENZB) had an operating margin of -38.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is ENZO BIOCHEM INC's net profit margin?

ENZO BIOCHEM INC (ENZB) had a net profit margin of -81.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is ENZO BIOCHEM INC's return on equity (ROE)?

ENZO BIOCHEM INC (ENZB) has a return on equity of -46.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is ENZO BIOCHEM INC's free cash flow?

ENZO BIOCHEM INC (ENZB) recorded an outflow of $26.8M in free cash flow during fiscal year 2024. This represents a 32.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ENZO BIOCHEM INC's operating cash flow?

ENZO BIOCHEM INC (ENZB) recorded an outflow of $26.3M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

What are ENZO BIOCHEM INC's total assets?

ENZO BIOCHEM INC (ENZB) had $85.8M in total assets as of fiscal year 2024, including both current and long-term assets.

What are ENZO BIOCHEM INC's capital expenditures?

ENZO BIOCHEM INC (ENZB) invested $545K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does ENZO BIOCHEM INC spend on research and development?

ENZO BIOCHEM INC (ENZB) invested $2.6M in research and development during fiscal year 2024.

How many shares does ENZO BIOCHEM INC have outstanding?

ENZO BIOCHEM INC (ENZB) had 52M shares outstanding as of fiscal year 2024.

What is ENZO BIOCHEM INC's current ratio?

ENZO BIOCHEM INC (ENZB) had a current ratio of 2.82 as of fiscal year 2024, which is generally considered healthy.

What is ENZO BIOCHEM INC's debt-to-equity ratio?

ENZO BIOCHEM INC (ENZB) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ENZO BIOCHEM INC's return on assets (ROA)?

ENZO BIOCHEM INC (ENZB) had a return on assets of -30.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

How does ENZO BIOCHEM INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2024, ENZO BIOCHEM INC (ENZB) held $52.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $26.3M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is ENZO BIOCHEM INC's Altman Z-Score?

ENZO BIOCHEM INC (ENZB) has an Altman Z-Score of -3.54, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ENZO BIOCHEM INC's Piotroski F-Score?

ENZO BIOCHEM INC (ENZB) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ENZO BIOCHEM INC's earnings high quality?

ENZO BIOCHEM INC (ENZB) reported a net loss of $26.1M while operations used $26.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ENZO BIOCHEM INC cover its interest payments?

ENZO BIOCHEM INC (ENZB) reported an operating loss of $12.4M against $197K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.